FDA Approves First Treatment for High-Grade Papillary-Only Bladder Cancer

The U.S. Food and Drug Administration (FDA) expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), in combination with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment. This marks the first FDA-approved treatment specifically for patients with this form of BCG-unresponsive bladder cancer.